Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition

被引:0
|
作者
Antonis S. Manolis
Theodora A. Manolis
Antonis A. Manolis
Helen Melita
机构
[1] Athens University School of Medicine,First Department of Cardiology
[2] Aghia Sofia University Hospital,undefined
[3] Patras University School of Medicine,undefined
[4] Onassis Cardiac Surgery Center,undefined
来源
Heart Failure Reviews | 2022年 / 27卷
关键词
Atrial fibrillation; Tachycardiomyopathy; Heart failure; Left ventricular dysfunction; Ablation;
D O I
暂无
中图分类号
学科分类号
摘要
Many patients with persistent, chronic, or frequently recurring paroxysmal atrial fibrillation (AF) may develop a tachycardiomyopathy (TCM) with left ventricular (LV) dysfunction and heart failure (HF), which is reversible upon restoration and maintenance of sinus rhythm, when feasible, or via better and tighter ventricular rate (VR) control. Mechanisms involved in producing this leading cause of TCM (AF-TCM) include loss of atrial contraction, irregular heart rate, fast VR, neurohumoral activation, and structural myocardial changes. The most important of all mechanisms relates to optimal VR control, which seems to be an elusive target. Uncontrolled AF may also worsen preexisting LV dysfunction and exacerbate HF symptoms. Data, albeit less robust, also point to deleterious effects of slow VRs on LV function. Thus, a J-shaped relationship between VR and clinical outcome has been suggested, with the optimal VR control hovering at ~ 65 bpm, ranging between 60 and 80 bpm; VRs above and below this range may confer higher morbidity and mortality rates. A convergence of recent guidelines is noted towards a stricter rather than a more lenient VR control with target heart rate < 80 bpm at rest and < 110 bpm during moderate exercise which seems to prevent TCM or improve LV function and exercise capacity and relieve TCM-related symptoms and signs. Of course, restoring and maintaining sinus rhythm is always a most desirable target, when feasible, either with drugs or more likely with ablation. All these issues are herein reviewed, current guidelines are discussed and relevant data are tabulated and pictorially illustrated.
引用
收藏
页码:2119 / 2135
页数:16
相关论文
共 50 条
  • [21] A case of applying left bundle branch pacing combined with atrioventricular node ablation to treat atrial fibrillation-induced heart failure
    Lahati HA
    Li-Yun HE
    Lei LI
    Jiang-Li HAN
    Shu-Wang LIU
    Yuan ZHANG
    Wei XU
    Wei GAO
    Journal of Geriatric Cardiology, 2021, 18 (06) : 492 - 497
  • [22] THE SAFETY AND FEASIBILITY OF FLECAINIDE USE IN ATRIAL FIBRILLATION-INDUCED CARDIOMYOPATHY
    Ibrahim, Rand
    Mekary, Wissam
    Bhatia, Neal K.
    Shah, Anand D.
    Westerman, Stacy
    De Lurgio, David B.
    Patel, Anshul M.
    Lloyd, Michael Shane
    El-Chami, Mikhael
    Merchant, Faisal M.
    Kiani, Soroosh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (12) : 31 - 31
  • [23] Atrial fibrillation-induced connexin 43 redistribution in atria of the goat
    Chowdhury, R. A.
    Dhillon, P. S.
    Kaba, R.
    Hall, M. C.
    Kirubakaran, S.
    Garratt, C. J.
    Peters, N. S.
    EUROPEAN HEART JOURNAL, 2005, 26 : 736 - 736
  • [24] Atrial fibrillation-induced connexin 43 redistribution in atria of the goat
    Dhillon, P
    Kaba, R
    Chowdhury, R
    Hall, MC
    Kirubakaran, S
    Garratt, CJ
    Peters, NS
    HEART, 2005, 91 : A43 - A43
  • [25] Atrial Fibrillation-Induced Cardiomyopathy Rhythm Is Gonna Get You
    Alahwany, Salaheldin
    Richardson, Travis D.
    Tandri, Harikrishna
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2024, 10 (05) : 882 - 884
  • [26] Impact of atrial fibrillation induced-tachycardiomyopathy in the outcome of catheter ablation
    Calvo, N.
    Bisbal, F.
    Gulu, E.
    Ramos, P.
    Tolosana, J. M.
    Arbelo, E.
    Berruezo, A.
    Sitges, M.
    Brugada, J.
    Mont, L.
    EUROPEAN HEART JOURNAL, 2012, 33 : 226 - 226
  • [27] Characterisation of patients who develop atrial fibrillation-induced cardiomyopathy
    Ahluwalia, Nikhil
    Honarbakhsh, Shohreh
    Abbass, Hakam
    Joshi, Abhishek
    Chow, Anthony W. C.
    Dhinoja, Mehul
    Petersen, Steffen Erhard
    Hunter, Ross J.
    Lloyd, Guy
    Schilling, Richard J.
    OPEN HEART, 2024, 11 (02):
  • [28] Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
    Guo, Yutao
    Lip, Gregory Y. H.
    Apostolakis, Stavros
    CURRENT VASCULAR PHARMACOLOGY, 2015, 13 (02) : 192 - 201
  • [29] Heart failure and atrial fibrillation: Is atrial fibrillation ablation in heart failure pointless or mandatory?
    Kantharia, Bharat K.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2024, 35 (03) : 530 - 537
  • [30] Atrial fibrillation and heart failure: Is atrial fibrillation a disease?
    Tilman, V.
    MEDICAL HYPOTHESES, 2014, 83 (03) : 299 - 301